NUAK2 and neoplasm: In parallel, analysis of tumor growth in vivo, using an orthotopic mouse mammary model, revealed robust tumor growth between 1 and 4 weeks in controls, whereas NUAK2 KOs displayed reduced tumor volume increases (Fig. 6c).